These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Comparative preclinical evaluation of Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651 [TBL] [Abstract][Full Text] [Related]
24. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467 [TBL] [Abstract][Full Text] [Related]
25. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842 [TBL] [Abstract][Full Text] [Related]
26. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate. Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400 [TBL] [Abstract][Full Text] [Related]
27. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649 [TBL] [Abstract][Full Text] [Related]
28. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates. Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653 [TBL] [Abstract][Full Text] [Related]
29. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Qi S; Hoppmann S; Xu Y; Cheng Z Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730 [TBL] [Abstract][Full Text] [Related]
30. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621 [TBL] [Abstract][Full Text] [Related]
31. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde. Rosik D; Thibblin A; Antoni G; Honarvar H; Strand J; Selvaraju RK; Altai M; Orlova A; Eriksson Karlström A; Tolmachev V Bioconjug Chem; 2014 Jan; 25(1):82-92. PubMed ID: 24344772 [TBL] [Abstract][Full Text] [Related]
32. ⁶⁸Ga-NODAGA-VEGF₁₂₁ for in vivo imaging of VEGF receptor expression. Kang CM; Koo HJ; Choe YS; Choi JY; Lee KH; Kim BT Nucl Med Biol; 2014 Jan; 41(1):51-7. PubMed ID: 24183611 [TBL] [Abstract][Full Text] [Related]
33. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. Beaino W; Anderson CJ J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059 [TBL] [Abstract][Full Text] [Related]
34. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874 [TBL] [Abstract][Full Text] [Related]
35. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701 [TBL] [Abstract][Full Text] [Related]
36. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791 [TBL] [Abstract][Full Text] [Related]
37. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516 [TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Altai M; Varasteh Z; Andersson K; Eek A; Boerman O; Orlova A Cancer Biother Radiopharm; 2013 Apr; 28(3):187-95. PubMed ID: 23461385 [TBL] [Abstract][Full Text] [Related]
39. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983 [TBL] [Abstract][Full Text] [Related]